SCHEMBL15519549

SCHEMBL15519549

Nc1ccc(-c2ccco2)cc1N

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 2/20 0.61
MEN1 O00255 1/20 0.52
KMT2A Q03164 1/20 0.52
TDP1 Q9NUW8 1/20 0.52
HDAC2 Q92769 1/20 0.51
PGR P06401 1/20 0.49
ERN1 O75460 1/20 0.46
ADORA2A P29274 2/20 0.45
KEAP1 Q14145 1/20 0.44
CHEK1 O14757 1/20 0.43
LPL P06858 1/20 0.43
LIPG Q9Y5X9 1/20 0.43
KDM4E B2RXH2 1/20 0.43
ALDH1A1 P00352 1/20 0.43
MAPT P10636 1/20 0.43
BLM P54132 1/20 0.43
PRMT6 Q96LA8 1/20 0.42
PDPK1 O15530 1/20 0.42
KCNH2 Q12809 1/20 0.41
SMARCA2 P51531 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3468657 0.82 TAAR1 (0.55) TAAR1TDP1HDAC2PGRERN1
SCHEMBL24196355 0.82 ALDH1A1 (0.57) TAAR1TDP1HDAC2PGRERN1
SCHEMBL26423596 0.81 TAAR1 (0.53) TAAR1MEN1KMT2ATDP1HDAC2
SCHEMBL24714531 0.80 TAAR1 (0.52) TAAR1HDAC2PGRERN1ADORA2A
SCHEMBL30820503 0.78 ADORA2A (0.56) TAAR1MEN1KMT2AERN1ADORA2A
SCHEMBL12121599 0.78 ERN1 (0.62) TAAR1HDAC2PGRERN1ADORA2A
SCHEMBL19475516 0.78 ADORA2A (0.56) TAAR1MEN1KMT2AERN1ADORA2A
SCHEMBL394300 0.77 TAAR1 (0.76) TAAR1MEN1KMT2ATDP1PGR
SCHEMBL23154128 0.76 HDAC2 (0.49) TAAR1HDAC2PGRERN1KEAP1
SCHEMBL1161258 0.76 TAAR1 (1.00) TAAR1MEN1KMT2ATDP1ADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102775356-B 4-aminoquinazoline derivative and application thereof JIANGSU HENGYI PHARMACEUTICAL CO LTD 2015-07-22 CN disclosed
US-9034886-B2 4-aminoquinazoline derivatives and uses thereof SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) 2015-05-19 US disclosed
WO-2014191358-A1 NOVEL COMPOUNDS WITH SEMICONDUCTING PROPERTIES SOLVAY SA (BE) 2014-12-04 WO disclosed
EP-2808373-A1 Semiconductor materials on the basis of rylene diimide derivatives or napththalene derivatives, and polymers and semiconductor devices comprising said materials Solvay SA (BE) 2014-12-03 EP disclosed
EP-2808327-A1 Novel compounds with semiconducting properties Solvay SA (BE) 2014-12-03 EP disclosed
US-20140235633-A1 4-Aminoquinazoline Derivatives and Uses Thereof SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) 2014-08-21 US disclosed
EP-2708532-A1 4-AMINOQUINAZOLINE DERIVATIVES AND USES THEREOF Jiangsu Hengyi Pharmaceutical Co.,Ltd (CN) 2014-03-19 EP disclosed
CN-102775356-A 4-aminoquinazoline derivative and application thereof JIANGSU HENGYI PHARMACEUTICAL CO LTD 2012-11-14 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140235633-A1 4-Aminoquinazoline Derivatives and Uses Thereof HDAC5, HDAC4, HDAC1 TAAR1 3337/4885MEN1 3655/4885KMT2A 14/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.